<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">Remdesivir is claimed to be an option to treat COVID-19 [
 <xref ref-type="bibr" rid="CR80">80</xref>]. It is a nucleoside analog and has broad-spectrum activities against RNA viruses such as MERS; remdesivir can effectively diminish the viral load in lung tissue infected with MERS-CoV and improve lung function in animal model [
 <xref ref-type="bibr" rid="CR81">81</xref>]. The in vitro study revealed that, compared with ribavirin or favipiravir, remdesivir in combination with emetine showed the inhibition in viral yield that might achieve 64.9% [
 <xref ref-type="bibr" rid="CR82">82</xref>]. Regarding its clinical application, Grein et al. reported the good improvement among severe COVID-19 cases (68%, 
 <italic>n</italic> = 53) after treatment with remdesivir [
 <xref ref-type="bibr" rid="CR83">83</xref>]. It also showed promising results in the treatment of a patient with COVID-19 in the USA [
 <xref ref-type="bibr" rid="CR84">84</xref>]. However, its efficacy is doubted because, e.g., in a randomized, double-blind, placebo-controlled, multicenter trial, Wang et al. reported no statistically significant clinical benefits [
 <xref ref-type="bibr" rid="CR85">85</xref>].
</p>
